Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 5/20 | 0.53 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MYLK | Q15746 | 1/20 | 0.42 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4499121 | 0.80 | CUL4A (0.49) | MAPTMEN1KMT2ACUL4A | |
| SCHEMBL5114538 | 0.79 | TACR1 (0.40) | JAK2JAK1TYK2MEN1KMT2A | |
| SCHEMBL4511855 | 0.79 | CUL4A (0.48) | MAPTMEN1KMT2ACUL4A | |
| SCHEMBL4492325 | 0.77 | CUL4A (0.42) | JAK2JAK1TYK2MAPTMEN1 | |
| SCHEMBL4498079 | 0.76 | CUL4A (0.45) | MAPTMEN1KMT2ACUL4A | |
| SCHEMBL4482553 | 0.76 | CUL4A (0.52) | MAPTCUL4A | |
| SCHEMBL4499607 | 0.76 | KDM4E (0.44) | POLB | |
| SCHEMBL4498718 | 0.75 | CUL4A (0.51) | MAPTMEN1KMT2ACUL4A | |
| SCHEMBL4489957 | 0.74 | POLB (0.37) | MEN1KMT2APOLB | |
| SCHEMBL4483473 | 0.73 | RXFP1 (0.49) | MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | TMPRSS4 798/4885P2RX1 2316/4885P2RX4 2294/4885 |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | HAVCR2, PYGL, HCCS | TMPRSS4 2745/4885P2RX1 193/4885P2RX4 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.